Inhibrx Biosciences Inc (INBX) AI Stock Analysis

• Market Cap: $186.16M
• Dividend Yield: N/A
• Average Volume (3M): 98.28K
• Price to Earnings (P/E): 0.1
• Beta (1Y): 0.54
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 156
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.80
• Shares Outstanding: 14,475,904
• 10 Day Avg. Volume: 96,410
• 30 Day Avg. Volume: 98,275
• PEG Ratio: -0.08
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.82
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: 3.09
• Enterprise Value/Gross Profit: -13.01
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $13.00 ▲(1.09%Upside)

Inhibrx Biosciences Inc's overall stock score is primarily impacted by its poor financial performance, characterized by revenue and cash flow challenges and high leverage. While technical indicators show some positive momentum, potential overbought conditions and high financial risk weigh heavily. Valuation suggests potential undervaluation, but caution is advised due to underlying financial issues.

Positive Factors

Clinical Efficacy

Ozekibart in combination with FOLFIRI showed a promising 40% objective response rate in the treatment of heavily pretreated CRC patients.

Financial Stability

Inhibrx is well capitalized with $196.3 million in cash, allowing continued development of its key treatments.

Progression-Free Survival

The 7.85-month median PFS shows promising results when compared to expected outcomes for 2L+ CRC.

Negative Factors

Liver Enzyme Levels

31% of patients experienced an increase in alanine aminotransferase, indicating potential safety issues.

Safety Concerns

A patient passed away due to neutropenic sepsis, raising concerns about the safety profile of the treatment.

Inhibrx Biosciences Inc Business Overview & Revenue Model

Company Description

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

How the Company Makes Money

Inhibrx Biosciences Inc generates revenue primarily through strategic partnerships, licensing agreements, and collaborations with larger pharmaceutical companies. These partnerships typically involve upfront payments, milestone payments based on the achievement of specific development, regulatory, and commercial goals, and royalty payments on sales of products that arise from the collaborations. Additionally, the company may receive funding from governmental and non-governmental grants to support its research and development activities. Inhibrx's business model relies heavily on the successful progression of its drug candidates through clinical trials, which can then attract further investment and partnership opportunities.

Inhibrx Biosciences Inc Financial Statement Overview

Summary

Inhibrx Biosciences Inc presents a mixed financial picture with significant operational challenges. The income statement highlights issues with revenue generation and profitability, while the balance sheet indicates high leverage and potential solvency risks. Cash flow issues further exacerbate these concerns, despite some external financing support. Overall, the company needs to address these challenges to achieve a more stable financial footing.

Income Statement

Inhibrx Biosciences Inc has faced significant challenges in revenue generation, with a decline from previous years and a negative EBIT and EBITDA margin indicating operational inefficiencies. Although there is a notable spike in net income for 2024, this appears to be an anomaly and not reflective of consistent profitability. Overall, the company struggles with achieving a sustainable revenue growth trajectory.

Balance Sheet

The company has shown some improvement in stockholders' equity, yet it remains heavily leveraged with a debt-to-equity ratio indicating high financial risk. The equity ratio is low, suggesting that the company relies significantly on debt financing, which could be risky if revenue does not improve. The high liabilities relative to assets further highlight potential solvency concerns.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing operational challenges. The free cash flow position is also negative, indicating limited internal generation of cash for reinvestment or debt repayment. However, the company has managed to secure external financing, which has supported liquidity but raises concerns about long-term financial sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
200.00K	1.80M	2.18M	7.13M	12.81M
	Gross Profit
-2.08M	609.00K	-668.00K	4.44M	-60.69M
	EBIT
-331.45M	-219.22M	-129.12M	-76.56M	-67.44M
	EBITDA
1.70B	-206.69M	-125.82M	-76.56M	-67.44M
	Net Income Common Stockholders
1.69B	-241.36M	-145.23M	-81.77M	-75.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
152.60M	277.92M	273.87M	131.30M	128.66M
	Total Assets
180.77M	307.89M	290.88M	150.45M	143.74M
	Total Debt
8.05M	210.14M	202.07M	70.47M	37.45M
	Net Debt
-144.55M	-67.78M	-71.80M	-60.83M	-91.21M
	Total Liabilities
47.18M	264.39M	232.82M	98.07M	68.27M
	Stockholders Equity
133.58M	43.50M	58.06M	52.38M	75.47M
Cash Flow		Free Cash Flow
-197.01M	-197.90M	-115.99M	-81.19M	-49.33M
	Operating Cash Flow
-194.41M	-193.31M	-115.30M	-80.32M	-47.97M
	Investing Cash Flow
-2.60M	-4.59M	-686.00K	-809.00K	-1.36M
	Financing Cash Flow
71.68M	201.96M	258.55M	83.77M	166.46M

Inhibrx Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 12.86 is above the 20-day moving average (MA) of 12.11, above the 50-day MA of 12.61, and below the 200-day MA of 14.00, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 58.08 is Neutral, neither overbought nor oversold. The STOCH value of 73.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.

Inhibrx Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	$4.84B	20.30	-16.90%	5.20%	13.60%	-28.06%
MGX	50 Neutral	$60.56M	―	-31.93%	―	-4.22%	18.67%
INBX	49 Neutral	$186.16M	0.11	3250.55%	―	―	―
ANRO	42 Neutral	$77.70M	―	-38.04%	―	―	―
CTNM	39 Underperform	$92.23M	―	-91.32%	―	-100.00%	-244.85%
FBLG	38 Underperform	$30.99M	―	-559.73%	―	―	―
KYTX	36 Underperform	$111.50M	―	-49.72%	―	―	―

Inhibrx Biosciences Inc Corporate Events

Inhibrx Biosciences Appoints New President Amid Leadership Changes

On April 1, 2025, Inhibrx Biosciences, Inc. announced the appointment of David J. Matly as President, effective immediately, while he continues his role as Chief Commercial and Business Development Officer. This strategic move is expected to leverage Matly’s extensive experience in commercial launch and business development, enhancing the company’s market position. Concurrently, Brendan P. Eckelman resigned as Chief Scientific Officer on March 31, 2025, to establish a new private biotechnology company, marking a significant shift in the company’s leadership dynamics.